BCM
SPRO icon

Bourgeon Capital Management’s Spero Therapeutics SPRO Stock Holding History

Bourgeon Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,100
Closed -$22.2K – 340
2023
Q4 		$22.2K Hold
15,100
– – ﹤0.01% 201
2023
Q3 		$18.3K Hold
15,100
– – ﹤0.01% 202
2023
Q2 		$21.9K Sell
15,100
-10,500
-41% -$18K 0.01% 202
2023
Q1 		$37.1K Buy
25,600
+12,500
+95% +$20.9K 0.01% 157
2022
Q4 		$22.7K Sell
13,100
-7,500
-36% -$14K 0.01% 193
2022
Q3 		$41K Buy
20,600
+3,000
+17% +$2.98K 0.01% 143
2022
Q2 		$13K Sell
17,600
-45,496
-72% -$132K ﹤0.01% 212
2022
Q1 		$549K Buy
63,096
+11,850
+23% +$121K 0.12% 70
2021
Q4 		$820K Buy
51,246
+9,500
+23% +$151K 0.17% 67
2021
Q3 		$769K Buy
+41,746
New +$670K 0.16% 68
2021
Q1 		– Sell
-15,341
Closed -$297K – 307
2020
Q4 		$297K Buy
+15,341
New +$239K 0.07% 90

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bourgeon Capital Management's SPRO Position: Q1 2024 in Review

Bourgeon Capital Management sold out of Spero Therapeutics (SPRO) in Q1 2024, closing a stake of 15,100 shares — an estimated $22.2K sold.

Bourgeon Capital Management first reported a position in SPRO in Q4 2020 and held it in 11 quarters. The position peaked at $820K in Q4 2021. 54 funds tracked by Wall St. Rank hold SPRO as of Q1 2024.

  • Bourgeon Capital Management reported no remaining Spero Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Bourgeon Capital Management sold 15,100 Spero Therapeutics shares in Q1 2024, an estimated $22.2K.
  • Bourgeon Capital Management first reported a position in Spero Therapeutics in Q4 2020 and held it in 11 quarters.
  • Bourgeon Capital Management's Spero Therapeutics position peaked at $820K in Q4 2021.
  • 54 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2024.

Based on Bourgeon Capital Management's 13F filing for Q1 2024, filed 19 Apr 2024.